
    
      Open-label, single arm, multi-center, Phase II interventional pilot trial. Primary objective
      will be to assess participant satisfaction with the decentralized clinical trial (DCT)
      experience.

      The trial will enroll men and pre- and post-menopausal women with a HR-positive/HER2-negative
      ABC (loco regionally recurrent not amenable to curative therapy or metastatic) with a PIK3CA
      mutation, which progressed on or after endocrine-based treatment.

      Participants will receive alpelisib 300 mg daily and fulvestrant 500 mg administered
      intramuscularly on Cycle 1, Day 1 and Cycle 1, Day 15, and on Day 1 of each cycle thereafter
      until Cycle 12.

      Pre-menopausal women will receive goserelin 3.6 mg on Day 1 of each cycle.
    
  